Publication

Article

Oncology & Biotech News

January 2011
Volume5
Issue 1

Inconclusive Lung Cancer Screenings Prompt Smokers to Quit

Men who undergo lung cancer screening are more likely to stop smoking if the results are inconclusive than if they are negative, according to a team of researchers from Denmark.

Men who undergo lung cancer screening are more likely to stop smoking if the results are inconclusive than if they are negative, according to a team of researchers from Denmark. The smokers with CT scans that were inconclusive made 1.9 attempts to quit compared with 1.5 for those FDA Updates with negative scans. In addition, 12% of men with inconclusive screens abstained from cigarettes for a prolonged period compared with 9% of the men with negative screens. Investigators noted that the differences were not statistically significant, but they said it suggests a need for more research to determine whether lung cancer screening could be a tool to promote smoking cessation. Findings were published in the European Respiratory Journal.

Related Videos
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.